Coronary Vasoconstriction After Percutaneous
Transluminal Coronary Angioplast Is Attenuated by Antiadrenergic Agents Luisa Gregorini, MD; Jean Fajadet, MD; Gabriel Robert, MD; Bernard Cassagneau, MD; Monique Bernis, MD; Jean Marco, MD Background Vasoconstriction occurs after percutaneous transluminal coronary angioplasty (PTCA) along the dilated vessel. The vasomotor changes, initiated by the mechanical stretch of the stenotic region, are thought to be due to various mechanisms but whether the sympathetic nervous system plays a role in this phenomenon remains unknown.
Methods and Results Quantitative angiography (ARTREK) was performed in 45 patients undergoing an epicardial vessel PTCA for a stenosis of 76±1% (1) in basal conditions, (2) after PTCA, and (3) 30 minutes after PTCA (vasoconstriction). In 14 control patients, the same measurements were obtained up to 60 minutes after PTCA. Coronary diameters were measured along the PTCA vessel at the narrowest stenosis level and at a level peripheral to stenosis. In 36 patients two diameters were also measured at a proximal segment and at a distal segment along a nonmanipulated vessel.
Thirty minutes after PTCA the dilated segment underwent a -31±2% (mean±SEM, ANOVA, P<.05) reduction in diameter when compared with PTCA values, and the segment peripheral to stenosis showed a reduction of -17±2% (P<.05).
In all patients a significant vasoconstriction also was observed along the control vessel (proximal segment, -14±3%; P<.05 versus basal; and distal segment, -17±2%). At the time of maximal vasoconstriction (30 minutes after PTCA), the patients (treatment groups) received (1) 18 ,ug/kg IC phentolamine (Phe, n=7), (2) 14 ,ug/kg IC yohimbine (YO, n=7), (3) 16 jg/kg IC propranolol (Pro) followed by 18 jig/kg IC phentolamine (Pro+Phe, n=7), and (4) 0.2 mg/kg IC bretylium (Bre, n=10). In 14 patients (control groups) an intracoronary injection of warm saline was given. After drug injections, angiograms were repeated at 5-minute intervals for 20 minutes and ended after a 300-pg intracoronary trinitroglycerin injection. At stenosis level, Phe and Bre counteracted vasoconstriction, inducing a dilatation of +19±3% and +22±6%, respectively, while Pro+Phe caused a dilatation of +16±9% above the PTCA values (P<.05 versus PTCA). YO only partially reversed vasoconstriction (from -33±4% to -12±4%, P=NS versus PTCA). At peripheral-to-stenosis level, vasoconstriction was abolished by Phe (+26±7%, P<.05 versus basal), while it was still present after Pro+Phe (-23±2%) and Bre (-18±4%). In addition, Phe and Bre dilated the control vessel at the proximal segment (+17±6% and +8±4%, respectively, P<.05 versus basal), while YO and Pro+Phe only counteracted vasoconstriction (from -15 ±3% to +7.6±1% and from -16±3% to +4±5%, respectively, P=NS versus basal). At the distal segment only Phe produced a vasodilatation of +23±1%; YO counteracted constriction (from -16±2% to +9±6%, P<.05 versus basal), whereas after Pro+Phe and Bre, the vasoconstriction persisted.
Conclusions The mechanical stretch and ischemia caused by balloon inflation induced vasoconstriction mediated by a-adrenergic receptors (mainly a,), overcoming a /-mediated dilatation.
The use of different antiadrenergic drugs showed that Phe counteracts post-PTCA vasoconstriction, and the simultaneous ing, the morphological effects of coronary angioplasty were visualized in humans. 5 The fracture of the plaque seems to be the crucial element in favoring the remodeling of the dilated vessel and perhaps in preventing restenosis. 5 The acute trauma caused on the atherosclerotic arterial wall by balloon inflation is thought to trigger complex vascular reactions after PTCA. Fischell and coworkers6'7 demonstrated that coronary artery vasoconstriction is initiated soon after the PTCA procedure, at the site of the dilated stenosis and along the distal segment of the same vessel. This vasoconstriction, which reaches a peak 30 minutes after PTCA, varies from 5% to 46% (mean, 30±4%) at the site of PTCA, and is less evident at the level of the distal segment,6,7 was reported to be rapidly reversed by intracoronary injection of 300 jig trinitroglycerin (TNG). If the artery is overstretched 
Study Protocol
The protocol was approved by the Clinique Pasteur ethical committee and is summarized in Fig 1. Any /3-blocking therapy was discontinued 72 hours before the study. Calcium-channel-blocking agents were withdrawn 24 hours before the procedure. Intravenous infusion of nitroglycerin and oral or percutaneous nitrates were discontinued 6 hours before the study. All patients received daily 325 mg acetylsalicylic acid and subcutaneous or intravenous heparin injections to obtain a clotting time between 50 and 70 seconds.
PTCA Procedure
Neuroleptic analgesia with droperidol (2 to 10 mg IV) and phenoperidine (0.6 to 1 mg IV) was administered during the PTCA procedure according to the standard protocol of the Clinique Pasteur. 22 With patients under local anesthesia obtained with 1% xylocaine, a femoral artery was cannulated with an 8F sheath introduced with a single-wall puncture technique.
Selective coronary visualization of the stenotic vessel was obtained with multiple projections to provide the most accurate evaluation of the arterial rami while avoiding visual vessel overlapping. The same projections were subsequently repeated for each step of the protocol. The angiographic images were acquired with a Philips-DCI single-plane system at a rate of 50 frames per second, with a 6.5 -in image intensifier mode. Meglumine ioxaglate (64 g iodine/200 mL) was used as a nonionic contrast medium.
Phasic and mean coronary blood flow (CBF) velocities (centimeters per second) were obtained with a pulsed Doppler flowmeter (Triton Technology, model 100-1000-20C) and 3.OF Doppler catheters (Nyros/Sorin) with the crystal mounted on the side of the catheter 5 mm from the distal tip. The technique has been fully validated.23-25 A 0.014-in ACS Traverse guide wire (300 cm long) was inserted far beyond the stenosis at the beginning of the procedure and left in place throughout the whole study. The Doppler catheter was positioned approximately 10 mm above the stenosis, far from any large branching vessel; its position was recorded on the DCI-Philips system so that the catheter could be replaced over the wire in the same position after PTCA. Two ECG leads PTCA was performed by a standard technique using either an over-the-wire or monorail balloon catheter system (ACS Prism, Cordis Europass, or Schneider Speedy balloon catheters). Heparin (15 000 U IV) was administered at the beginning of the procedure with an additional 5000 U after 90 minutes.
The number of inflations and the amount of pressure were left to the experience of the operator, but at least two balloon inflations were performed to obtain a satisfactory result. The result was first checked with angiograms in three projections (PTCA). To determine the diameters of the vessel in a state of maximal dilatation28 soon after PTCA, two angiograms were recorded in 10 patients and 7 control subjects after the intracoronary injection of 300 ,ug TNG (PTCA-TNG). In (30 minutes) , the angiograms and all other measures were repeated (Fig 1) .
Thereafter, different antiadrenergic drugs were injected through the 8F guiding catheter at the coronary ostium to distribute the drug along the coronary branches. In 7 patients, 18 pg/kg phentolamine (Regitin, 10-mg vials, IC, Ciba-Geigy) was administered through the guiding catheter at the coronary ostium to assess the specific effects of a nonselective a-adrenergic blocking agent on coronary diameters in the presence of vasoconstriction. The intracoronary dose was titrated to obtain local a-adrenergic block without significantly modifying systemic BP and heart rate (HR).29
In 7 other patients, 14 ,ug/kg of a stereoisomer of rauwolscine, yohimbine chlorate (1-mg vials, IC, G. Streuli & Co AG), was injected to obtain an a2-selective blockade. The yohimbine dose was derived from the dose known to exert an a2-blocking action in animal studies,30 and we doubled the dose used in humans by other authors.31 To subtract the possible contribution of a 1-vasodilator tone, we injected 7 other patients through the guiding catheter with 16 Mug/kg propranolol (Inderal, 5-mg vials, IC, ICI Pharma) followed by 18 ,ug/kg phentolamine.
To investigate the time course of pharmacological interventions on coronary artery diameters, we performed sequential angiograms every 5 minutes for 20 minutes. In 7 control patients, after measuring vasoconstriction 30 minutes after PTCA, we injected 5 mL of intracoronary warm saline, and we repeated the measurements after 30 minutes (60 minutes after PTCA). In 10 other patients, 0.2 mg/kg bretylium tosylate (Bretylate, 100-mg vials, IC, kindly supplied by Wellcome Spa) was injected through the guiding catheter. The intracoronary dose was calculated by multiplying the dose known to be capable of exerting a full adrenergic blockade when administered systemically (10 mg/kg)32-34 by the ratio of CBF to cardiac output (CO) as follows: intracoronary dose=(total systemic dose) x (CBF/CO). CO was calculated by multiplying HR and angiographic stroke volume.
The 10 patients receiving bretylium were those in whom 300
jg TNG IC were injected after PTCA (PTCA-TNG) (see above and Fig 1) .
In all patients, 300 jig TNG IC was administered at the end of the study.6'11 '28 Quantitative Angiogram Analysis A catheter stem of known size and full of contrast medium was used for calibration: we analyzed the 35-mm cine frames by a geometric and densitometric quantitative analysis. The system is based on a computerized and automated edgecontour detection analysis (ARTREK) that has been validated and described in detail by Mancini et al. 27 The frames were automatically corrected for radiographic pincushion distortion. To minimize potential influences of collateral branching on automatic diameter determination, reported measurements were taken only at arterial sections free of branches. An end-diastolic frame was carefully selected; 16 diameters along the stenosed vessel of each patient (approximately every 8 mm on the ARTREK screen) and 10 diameters along the control vessel in which no major atherosclerotic plaques were present (stenosis <20%) were determined (Fig 2) . The diameters reported in this paper are 2 of 16 measured along the PTCA vessel and 2 of 10 along the control vessel. Each diameter was measured three times by ARTREK, and the values were averaged for each projection; this was performed at each step of the protocol. The same measurements were calculated in an orthogonal projection, and the values reported are the mean of the values obtained in left lateral and in right anterior oblique view (Fig 1) . As to the terminology used, "stenosis" indicates the level of the narrowest point of the stenotic segment ( Fig 2) ; "peripheral to stenosis" corresponds to a peripheral segment as already described by others.67'11 The measurements along the nonmanipulated control vessel were calculated corresponding to its proximal and distal site (Fig 2) . To measure coronary diameters at the same level, for each patient we drew the silhouette of the basal angiogram and its branches on a transparent sheet, subsequently repeating the same determinations at the same level and with the automatic ARTREK program. The quantitative images were also compared with hand-held caliper determinations. No significant differences in mean percent diameter determinations were found.
Statistical Analysis
The results are expressed as mean±SEM. One-way ANOVA for repeated measures using the Fisher correction for multiple comparison for paired data was performed as appropriate. In the tables, both absolute and normalized (%) values are presented. In view of the large interindividual variability of absolute values, multiple comparisons between groups were performed with normalized data. Regression analysis was performed using least-squares techniques. A value ofP<.05 was considered significant.
Results

Hemodynamic Results
No significant changes in MAP were detected 30 minutes after PTCA and 10, 15, and 20 minutes after intracoronary injection of different drugs compared with basal conditions. A significant reduction of MAP (from 90.5 ±2 to 74±1 mm Hg) and an increase of HR (from 68.8±2 to 82±3 beats per minute) were observed after intracoronary nitroglycerin injection, except in the group of patients who received an intracoronary injection of 16 ,ug/kg propranolol, in whom HR did not increase over basal (Fig 4 and Table 4 ).
In the 14 patients who received intracoronary warm saline instead of antiadrenergic agents (see "Methods"), measurements were performed also at 60 minutes to address the time course of vasoconstriction after PTCA (Figs 1 and 3 ). Sixty minutes after PTCA, the diameters of both the stretched and the control vessels were still significantly decreased (Fig 3, Tables 1  through 4) .
In 28 patients (without TNG) the correlation between the diameter of stenosis and the degree of vasoconstriction was found not significant (r=.106, P=NS).6,7,10
Effects of Phentolamine
In the 7 patients in whom intracoronary phentolamine was injected after PTCA, the vasoconstrictor response was abolished and reversed into a significant vasodilatation above the PTCA values within 15 minutes. This phenomenon was observed at the level of angioplasty (Fig 4, Table 1) , at a peripheral level of the same stretched vessel (Fig 4, Table 2 ), and at both the proximal and distal levels of the nonmanipulated vessel (Fig 4, Tables 3 and 4) . It should be noted that the subsequent administration of nitroglycerin (about 60 minutes after PTCA) did not induce any further coronary vasodilatation.
Effects of Yohimbine
In contrast to what was observed after phentolamine administration, yohimbine counteracted only part of the constriction at the stenosis level observed 30 minutes after PTCA, reducing the decrease in diameter from -33±4% to -12±4% (P=NS versus PTCA) (Fig 4,   Table 1 ). The final nitroglycerin injection was also incapable of reverting the vasoconstriction at the site of angioplasty. At the peripheral-to-stenosis site, yohimbine counteracted the -20±4% constriction observed 30 minutes after PTCA, increasing the diameter to +7.94±2.4%, which was not significantly different from basal values (Fig 4, Table 2 ). Yohimbine counteracted vasoconstriction also along the nonmanipulated vessel (Fig 4, Tables 3 and 4) .
Effects of Propranolol and Phentolamine
In 7 additional patients, the intracoronary injection of phentolamine was preceded by the injection of 16 ,ug/kg propranolol (see "Methods"). At the level of the stretched segment, the combined action of the two drugs induced effects that were not different from those observed after phentolamine alone (Fig 4, Table 1 ). Conversely, at the level of the segment peripheral to stenosis, a significant vasoconstriction was observed 10 and 15 minutes after injections (Fig 4, Table 2 ). Similarly, at the distal level of the nonmanipulated vessel, the administration of the two drugs showed the persistence of the vasoconstriction (Fig 4, Table 4 ). Effects of Bretylium Five minutes after the intracoronary injection of bretylium (0.2 mg/kg), there was a small and significant increase in arterial pressure (+ 16±4 mm Hg), which likely depends on norepinephrine released by postganglionic adrenergic nerve terminals.32-34 As soon as the BP returned to basal values, the stretched segment progressively dilated, reaching values of 2.11±0.08 mm 20 minutes after bretylium, similar to the 2.13±0.1 mm (P<.05 versus PTCA) observed after nitroglycerin injection (Fig 4, Table 1 ).
In addition, after bretylium injection, the segment peripheral to stenosis underwent a clear reduction in diameter with respect to basal conditions (from 1.85±0.09 mm basal to 1.5±0.1 mm 20 minutes after bretylium, P<.05) (Fig 4, Table 2 ). The nonmanipulated control vessel also displayed a reduction in diameter at its distal level after bretylium injection (from 2.46±0.24 to 2.08±0.49 mm corresponding to -15±2%, P<.05 versus basal) (Fig 4, Table 4 ). Fig 5 shows selected end-diastolic angiograms of a patient who had a severe proximal left anterior descending lesion. The successful dilatation is documented after TNG injection. However, after 30 minutes a severe reduction in diameter occurred at the site of dilatation (-39%), which was no longer present 20 minutes after bretylium injection.
In Fig 6 a proximal left anterior descending lesion is presented in basal conditions and after a successful angioplasty. A diameter reduction of 20% appears 30 minutes after PTCA at the site of the lesion, whereas it is no longer present 20 minutes after bretylium injection. In addition, a simultaneous marked vasoconstriction is present at the level of the peripheral segment of the same vessel and along the diagonal branch.
CBF Velocity and CVRi
The data of CBF velocity are reported in percent changes from basal values and have been grouped for all patients in similar conditions, ie, after PTCA and 30 minutes after PTCA (Fig 7) . CBF velocity was 9.2±0.6 cm/s in basal conditions, increased by +21±6% after angioplasty (P<.05), and decreased by -8±6% 30 minutes after PTCA (P=NS). All drugs, except propranolol followed by phentolamine, increased CBF velocity, reaching maximum values after phentolamine (+29±8%, from 6.72±0.6 cm/s) (Fig 7) . CSA (Fig 7) . As previously described by others,35-37 CVRi remained unchanged (-8±4%) soon after PTCA, but a consistent increase in resistance was observed during vasoconstriction (30 minutes after PTCA) (+53±15%). In contrast, phentolamine markedly reduced CVRi, which reached the smallest values observed throughout the study at 15 minutes (A% -35±4). Bretylium reduced CVRi somewhat without reaching significance (Fig 7) .
When propranolol and phentolamine were administered together, the reduction in CVRi appeared blunted when compared with phentolamine alone (Fig 7) . Yohimbine alone failed to decrease CVRi (A% -15 ± 1, P=NS) (Fig 7) . Discussion The present study demonstrates that a-adrenergic blockade with phentolamine counteracts the coronary vasoconstriction that follows PTCA.
We have shown that in patients undergoing a PTCA procedure for severe coronary stenosis, complex vasomotor changes subsequently take place both in the dilated vessel and in other branches of the coronary tree. As already reported by Fischell et al6'7 and by El Tamimi et al,1 "spontaneous vasoconstriction," indicated by a reduction in diameter, occurs after PTCA at the site of the stretched stenosis and along the peripheral segment. In addition, in our studies a similar vasoconstriction was observed also along the control vessel. These vasomotor changes occurring along the nonmanipulated vessel had not been previously reported.6,7,'1 Fischell and coworkers,6'7 who studied patients under treatment with different drugs (diltiazem, nifedipine, dipyridamole, or 8-blockers) observed that the arterial wall, although overstretched by angioplasty, retains vasoconstrictor and vasodilator capabilities. They attributed this vasoconstriction to a reset of the autoregulatory responsiveness of a hypoperfused coronary segment becoming abruptly exposed to a higher perfusion pressure6'7"13: in their study the degree of vasoconstriction correlated to the severity of the stenosis. 6 In contrast, in our study and in the study by El Tamimi et all' the degree of vasoconstriction did not correlate with the severity of the stenosis.
The vasoconstriction was also attributed to factors such as thrombus formation, with the consequent release of serotonin and thromboxane A2 by platelets adhering to the plaque deprived of endothelium.6,11 '4-19 Vasoconstrictor factors released by platelets are likely to produce a more marked constriction in the absence of endothelium,1415,38 and a specific serotonin-receptor antagonist seems to prevent proximal but not distal vasoconstriction after PTCA. 39 However, in our study a vasoconstriction was also observed on coronary vessels not emerging from the stretched segment, thus making it unlikely that local platelet adhesion was the only triggering mechanism. An impaired release of endothelium-derived relaxing factors has also been implicated": specifically, it was suggested that angioplasty fractures and ablates endothelium.3-5 Moreover, nitroglycerin, which is thought to produce its biological effects by releasing nitric oxide40 and thus mimicking the endothelium-derived relaxing factor,41 when injected at the end of the study failed to counteract the vasoconstriction present 60 minutes after PTCA in our control patients. Although our data do not fully exclude the above hypotheses, they suggest that an additional a-adrenergic mechanism is involved.
Coronary Vasoconstriction and Sympathetic Mechanisms
The efficacy of the different test drugs used in this study for modulating coronary vasomotion and counteracting the vasoconstriction occurring after angioplasty suggests that a sympathetic mechanism is playing an important role. This neural effect would not preclude the possibility that other factors, like those suggested by previous authors,6,7"1might be active as well. Coronary sympathetic mechanoreceptors21 could be excited by both mechanical distension of the vessel (at the site of the stenosis) and by the increased coronary pressure acting on the peripheral tract of the vessel after PTCA. A similar mechanism was postulated by Fouad The vasodilatation induced by phentolamine appeared reduced, in the present study, by the concomitant administration of intracoronary propranolol in accordance with prior observations in conscious dogs that indicated the presence of /3-receptor-mediated coronary vasodilatation. 53, 63, 64 To further clarify the role of adrenergic receptors in post-PTCA vasoconstriction, we administered bretylium tosylate by intracoronary injection; it is a quaternary benzylammonium drug that, interfering with noradrenaline release, possesses both a-and ,/-receptor sympatholytic activity but lacks the undesirable effects of parasympathetic blockers.32-34 Indeed, it has a specific affinity for noradrenaline storage compartments of sympathetic nerve endings, interfering with the release of endogenous stores of norepinephrine without significantly altering the ultrastructural integrity of adrenergic neural vesicles. 65 The effects observed after intracoronary administration of bretylium paralleled those observed after the combination of propranolol and phentolamine. In fact, in both instances coronary diameter at the site of stenosis was markedly increased, while peripherally it was decreased, suggesting an important role of P-receptor-mediated vasodilator effects, particularly at peripheral sites. This concept appears in agreement with prior observations in conscious dogs that had indicated the presence of a significant /3-receptormediated vasodilatation in epicardial coronary arterieS. 53, 63, 64 
Conclusions
Neural mechanisms are likely to play a relevant role, especially in the absence of normal endothelium, in favoring the marked vasoconstrictor response that follows the coronary stretch induced by angioplasty. The pharmacological possibility of preventing these responses might modify the subsequent outcome. Accordingly, new strategies for the prevention and treatment of restenoses might include antiadrenergic interventions. 
